News - Page 169 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Post published:June 24, 2021
Post category:Press Release

Read more about the article Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

Post published:June 23, 2021
Post category:Press Release

Read more about the article MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues

MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues

Post published:June 23, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences to Commence Trading on the NEO Exchange under the Symbol ‘AWKN’

Awakn Life Sciences to Commence Trading on the NEO Exchange under the Symbol ‘AWKN’

Post published:June 23, 2021
Post category:Press Release

Read more about the article MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

Post published:June 23, 2021
Post category:Press Release

Read more about the article COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme

COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme

Post published:June 23, 2021
Post category:Press Release

Read more about the article PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie

PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie

Post published:June 22, 2021
Post category:Press Release

Read more about the article Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Post published:June 22, 2021
Post category:Press Release

Read more about the article Interview: Dr. Josh Woolley (TrPR) and Ben Lightburn (Filament Health)

Interview: Dr. Josh Woolley (TrPR) and Ben Lightburn (Filament Health)

Post published:June 22, 2021
Post category:Interview

Read more about the article Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

Post published:June 22, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.